Praedicare Inc. Receives Grant to Evaluate Potential New Drug Regimens for Tuberculosis

Praedicare Inc., announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel Tuberculosis (TB) drug regimens using Praedicare’s in vitro hollow fiber model of TB in identifying potential new drug regimens that shorten treatment times for the disease.